Trulicity ® (dulaglutide)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Trulicity Summary of Product Characteristics (SmPC)

Trulicity® (dulaglutide): Use in Patients With COVID-19 (Coronavirus disease 2019)

Lilly has not studied the use of Trulicity (dulaglutide) in patients with COVID-19, nor in patients at risk of contracting COVID-19.

Use of Dulaglutide in a Patient with COVID-19

COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, previously referred to as "2019 novel coronavirus."1

Lilly has not studied the use of Trulicity in patients with COVID-19 nor in patients at risk of contracting COVID-19.

According to the dulaglutide label, respiratory infections are not listed as a warning or precautions for use of dulaglutide.2

Clinicians should use their clinical judgment in determining the most appropriate approach in treating a T2DM patient with confirmed or suspected COVID-19.

Infectious Disease Resources for COVID-19

For current information on COVID-19, please refer to

References

1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it

2. Trulicity [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.

3. Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 20, 2020. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19

4. International Diabetes Federation Europe. COVID-19 outbreak: guidance for people with diabetes. https://www.idf.org/our-network/regions-members/europe/europe-news/196-information-on-corona-virus-disease-2019-covid-19-outbreak-and-guidance-for-people-with-diabetes.html. Accessed March 18, 2020

5. COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020. https://www.ecdc.europa.eu/en/novel-coronavirus-china

Glossary

COVID-19 = coronavirus disease 2019

ECDC = European Centre for Disease Prevention and Control

EU WHO = World Health Organization (European regional office)

IDF = International Diabetes Federation

Lilly = Eli Lilly and Company

SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

Date of Last Review: March 16, 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question